Literature DB >> 26531829

Impacts of nicorandil on infarct myocardium in comparison with nitrate: assessed by cardiac magnetic resonance imaging.

Kiyoyasu Yamada1, Satoshi Isobe2, Hideki Ishii2, Kazuhiko Yokouchi3, Hirokazu Iwata3, Ken Sawada3, Toyoaki Murohara2.   

Abstract

In this pilot study, we compared the infarct and edema size in acute myocardial infarction (MI) patients treated by nicorandil with those treated by nitrate, using cardiac magnetic resonance (CMR) imaging. Fifty-two acute MI patients who underwent emergency percutaneous coronary intervention (PCI) were enrolled, and were assigned to receive nicorandil or nitrate at random just before reperfusion. For the assessment of infarct and edema areas, short-axis delayed enhancement (DE) and T2-weight (T2w) CMR images were acquired 6.1 ± 2.4 days after the onset of MI. A significant correlation was observed between the peak creatinine kinase (CK) level and the infarct size on DE CMR (r = 0.62, p < 0.05), as well as the edema size on T2w CMR (r = 0.70, p < 0.05) in patients treated by nicorandil (28 patients). A similar correlation was seen between the peak CK level and the infarct size on DE CMR (r = 0.84, p < 0.05), as well as the edema size on T2w CMR (r = 0.84, p < 0.05) in patients treated by nitrate (24 patients). The maximum CK level was significantly lower in patients treated by nicorandil rather than nitrate (1991 ± 1402, 2785 ± 2121 IU/L, respectively, p = 0.03). Both the edema size on T2w CMR and the infarct size on DE CMR were significantly smaller in patients treated by nicorandil rather than nitrate (17.7 ± 9.9, 21.9 ± 13.7 %; p = 0.03, 10.3 ± 6.0, 12.7 ± 6.9 %, p = 0.03, respectively). The presence and amount of microvascular obstruction were significantly smaller in patients treated by nicorandil rather than nitrate (39.2, 64.7 %; p = 0.03; 2.2 ± 1.3, 3.4 ± 1.5 cm(2); p = 0.02, respectively). Using CMR imaging, we demonstrated that the complementary use of intravenously and intracoronary administered nicorandil during PCI favorably acts more on the damaged myocardium after MI than nitrate. We need a further powered prospective study on the use of nicorandil.

Entities:  

Keywords:  Acute myocardial infarction; Delayed enhancement; Nicorandil; Nitrate; T2-Weight cardiac magnetic resonance imaging

Mesh:

Substances:

Year:  2015        PMID: 26531829     DOI: 10.1007/s00380-015-0752-3

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  32 in total

Review 1.  Coronary microembolization.

Authors:  R Erbel; G Heusch
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

2.  Safety and optimal protocol of provocation test for diagnosis of multivessel coronary spasm.

Authors:  Shozo Sueda; Toru Miyoshi; Yasuhiro Sasaki; Tomoki Sakaue; Hirokazu Habara; Hiroaki Kohno
Journal:  Heart Vessels       Date:  2014-11-01       Impact factor: 2.037

3.  Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction.

Authors:  Y Sakata; K Kodama; K Komamura; Y J Lim; F Ishikura; A Hirayama; M Kitakaze; T Masuyama; M Hori
Journal:  Am Heart J       Date:  1997-06       Impact factor: 4.749

4.  Subacute myocardial infarction: assessment by STIR T2-weighted MR imaging in comparison to regional function.

Authors:  S Miller; U Helber; U Kramer; U Hahn; J Carr; N I Stauder; H M Hoffmeister; C D Claussen
Journal:  MAGMA       Date:  2001-08       Impact factor: 2.310

5.  Additive effects of nicorandil on coronary blood flow during continuous administration of nitroglycerin.

Authors:  A Okamura; H Rakugi; M Ohishi; Y Yanagitani; M Shimizu; T Nishii; Y Taniyama; T Asai; S Takiuchi; K Moriguchi; M Ohkuro; N Komai; K Yamada; N Inamoto; A Otsuka; J Higaki; T Ogihara
Journal:  J Am Coll Cardiol       Date:  2001-03-01       Impact factor: 24.094

6.  Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms.

Authors:  J A Lima; R M Judd; A Bazille; S P Schulman; E Atalar; E A Zerhouni
Journal:  Circulation       Date:  1995-09-01       Impact factor: 29.690

7.  Feasibility and safety of intracoronary nicorandil infusion as a novel hyperemic agent for fractional flow reserve measurements.

Authors:  Daiki Kato; Hiroaki Takashima; Katsuhisa Waseda; Akiyoshi Kurita; Yasuo Kuroda; Takashi Kosaka; Yasushi Kuhara; Hirohiko Ando; Kazuyuki Maeda; Soichiro Kumagai; Shinichiro Sakurai; Akihiro Suzuki; Yukiko Toda; Atsushi Watanabe; Shigeko Sato; Masanobu Fujimoto; Tomofumi Mizuno; Tetsuya Amano
Journal:  Heart Vessels       Date:  2014-04-19       Impact factor: 2.037

8.  The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance.

Authors:  Matthias G Friedrich; Hassan Abdel-Aty; Andrew Taylor; Jeanette Schulz-Menger; Daniel Messroghli; Rainer Dietz
Journal:  J Am Coll Cardiol       Date:  2008-04-22       Impact factor: 24.094

9.  Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels.

Authors:  K Akai; Y Wang; K Sato; N Sekiguchi; A Sugimura; T Kumagai; T Komaru; H Kanatsuka; K Shirato
Journal:  J Cardiovasc Pharmacol       Date:  1995-10       Impact factor: 3.105

10.  The "no-reflow" phenomenon after temporary coronary occlusion in the dog.

Authors:  R A Kloner; C E Ganote; R B Jennings
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

View more
  7 in total

1.  The effect of nicorandil in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Authors:  Zhenjun Ji; Rui Zhang; Wenbin Lu; Genshan Ma; Yangyang Qu
Journal:  Ir J Med Sci       Date:  2019-05-30       Impact factor: 1.568

2.  Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.

Authors:  Yanming Fan; Qingmin Wei; Junna Cai; Yongtang Shi; Youliang Zhang; Limei Yao; Xiaogang Wang; Shupo Lin; Yilin Li; Jing Lv; Bin Zhou; Ruijuan Du
Journal:  Heart Vessels       Date:  2016-02-13       Impact factor: 2.037

3.  Nicorandil Improves Left Ventricular Myocardial Strain in Patients With Coronary Chronic Total Occlusion.

Authors:  Shaomin Chen; Chen Ma; Xinheng Feng; Ming Cui
Journal:  Front Cardiovasc Med       Date:  2022-05-12

Review 4.  Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis.

Authors:  Xiaowei Niu; Jingjing Zhang; Ming Bai; Yu Peng; Shaobo Sun; Zheng Zhang
Journal:  BMC Cardiovasc Disord       Date:  2018-01-10       Impact factor: 2.298

5.  Meta-analysis of Nicorandil effectiveness on myocardial protection after percutaneous coronary intervention.

Authors:  Xiao-Tao Zhao; Chun-Fei Zhang; Qing-Jie Liu
Journal:  BMC Cardiovasc Disord       Date:  2019-06-14       Impact factor: 2.298

Review 6.  Nicorandil prior to primary percutaneous coronary intervention improves clinical outcomes in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.

Authors:  Li Xu; Lefeng Wang; Kuibao Li; Zhiyong Zhang; Hao Sun; Xinchun Yang
Journal:  Drug Des Devel Ther       Date:  2019-04-29       Impact factor: 4.162

7.  Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Ning Geng; Li Ren; Lisheng Xu; Deling Zou; Wenyue Pang
Journal:  BMC Cardiovasc Disord       Date:  2021-10-10       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.